Stock Events

Organon 

M$339.32
427
+M$0+0% Monday 20:00

Statistics

Day High
339.32
Day Low
339.32
52W High
371
52W Low
189
Volume
0
Avg. Volume
1
Mkt Cap
151.29B
P/E Ratio
7.15
Dividend Yield
5.53%
Dividend
18.78

Upcoming

Dividends

5.53%Dividend Yield
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
17.84%
1Y Growth
-4.65%

Earnings

2MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
0
0.44
0.88
1.32
Expected EPS
0.93
Actual EPS
1.22

People Also Follow

This list is based on the watchlists of people on Stock Events who follow OGN.MX. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap169.83B
Pfizer is a global pharmaceutical company that competes with Organon in the areas of women's health and biosimilars, making it a direct competitor.
Merck &
MRK
Mkt Cap318.55B
Merck, the former parent company of Organon, competes in the pharmaceutical sector, including women's health and vaccine products.
Abbvie
ABBV
Mkt Cap304.29B
AbbVie competes with Organon in the pharmaceuticals sector, particularly in women's health, with a focus on therapies and treatments.
Johnson & Johnson
JNJ
Mkt Cap372.29B
Johnson & Johnson is a diversified healthcare giant that competes across various segments, including pharmaceuticals relevant to Organon's market.
AMGEN
AMGN
Mkt Cap177.72B
Amgen is a biopharmaceutical company that competes with Organon in the biosimilars market, offering alternative products.
Novo Nordisk
NVO
Mkt Cap445.94B
Novo Nordisk is a global healthcare company that, through its biopharmaceutical products, competes with Organon in areas like hormone replacement therapies.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap19.04B
Teva Pharmaceutical Industries is a global leader in generic and specialty medicines, competing with Organon in the generics and women's health market.
Bristol-Myers Squibb
BMY
Mkt Cap86.44B
Bristol Myers Squibb is a global biopharmaceutical company that competes with Organon in developing and commercializing prescription pharmaceuticals.
GSK
GSK
Mkt Cap81.55B
GlaxoSmithKline is a global healthcare company that competes with Organon in pharmaceuticals and vaccines, including areas of women's health.
Sanofi
SNY
Mkt Cap128.21B
Sanofi is a global biopharmaceutical company focusing on human health, competing with Organon in healthcare solutions, including women's health.

About

Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.
Show more...
CEO
Mr. Kevin Ali
Employees
10000
Country
United States
ISIN
US68622V1061
WKN
000A3CPKP

Listings